Daniel Ahn

Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

Abstract Background Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the stan...